HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ASND

Ascendis Pharma A/S ADR

Last Close
Dec 20 • 04:00PM ET
136.38
Dollar change
-1.36
Percentage change
-0.99 		%
Healthcare • Biotechnology • Denmark • NASD
Peers: BIIB INCY NBIX REGN VRTX SRPT NKTR DNLI EXEL ADVM
 | Held by: IBB MSSM SPDW TCAF FDG HRTS MEDI PFUT ONEQ TMAT
Scroll to Statements
Index- P/E- EPS (ttm)-8.10 Insider Own0.86% Shs Outstand59.76M Perf Week5.01%
Market Cap8.15B Forward P/E- EPS next Y-3.99 Insider Trans0.00% Shs Float59.25M Perf Month9.65%
Income-462.37M PEG- EPS next Q-1.36 Inst Own105.10% Short Float6.36% Perf Quarter-6.97%
Sales354.45M P/S22.99 EPS this Y15.45% Inst Trans5.43% Short Ratio7.96 Perf Half Y5.40%
Book/sh-1.82 P/B- EPS next Y46.69% ROA-43.11% Short Interest3.77M Perf Year12.56%
Cash/sh11.68 P/C11.67 EPS next 5Y38.10% ROE-867.62% 52W Range111.09 - 161.00 Perf YTD8.28%
Dividend Est.- P/FCF- EPS past 5Y-19.87% ROI-171.47% 52W High-15.29% Beta0.64
Dividend TTM- Quick Ratio0.84 Sales past 5Y182.00% Gross Margin80.51% 52W Low22.77% ATR (14)5.18
Dividend Ex-Date- Current Ratio1.16 EPS Y/Y TTM28.89% Oper. Margin-96.61% RSI (14)55.68 Volatility4.39% 3.76%
Employees- Debt/Eq- Sales Y/Y TTM117.15% Profit Margin-130.45% Recom1.00 Target Price195.79
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q39.60% Payout- Rel Volume1.34 Prev Close137.74
Sales Surprise-20.43% EPS Surprise-6.35% Sales Q/Q21.59% EarningsNov 14 AMC Avg Volume473.21K Price136.38
SMA202.07% SMA505.28% SMA2000.94% Trades Volume632,702 Change-0.99%
Date Action Analyst Rating Change Price Target Change
Sep-05-24Upgrade Oppenheimer Perform → Outperform $180
Jun-25-24Upgrade TD Cowen Hold → Buy $156 → $175
May-31-24Initiated Stifel Buy $200
Dec-20-23Initiated Jefferies Buy $150
Jun-14-23Resumed Credit Suisse Neutral $89
Apr-05-23Downgrade Oppenheimer Outperform → Perform
Apr-04-23Downgrade Morgan Stanley Overweight → Equal-Weight $151 → $108
Apr-03-23Downgrade Credit Suisse Outperform → Neutral
Oct-20-22Initiated Goldman Buy $174
Aug-30-22Resumed Berenberg Buy $166
Show Previous Ratings
Dec-19-24 08:30AM
YORVIPATH (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
(GlobeNewswire)
Dec-18-24 06:28AM
Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk
(TipRanks)
Dec-16-24 08:30AM
New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26
(GlobeNewswire) +5.18%
Dec-12-24 04:01PM
FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency
(GlobeNewswire)
Dec-11-24 11:09AM
Er-Kim and Ascendis endocrine therapy agreement extended in Eurasia
(Pharmaceutical Technology)
07:00AM Loading…
Dec-10-24 07:00AM
Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets
(GlobeNewswire)
Nov-14-24 04:01PM
Ascendis Pharma Reports Third Quarter 2024 Financial Results
(GlobeNewswire)
Nov-07-24 04:01PM
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
(GlobeNewswire)
Nov-05-24 12:12PM
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
(Pharmaceutical Technology)
10:00AM
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology
(GuruFocus.com)
07:27AM
Ascendis Pharma and Novo Nordisk Join Forces
(TipRanks)
07:10AM
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
(TipRanks)
Nov-04-24 03:30PM
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug
(Quartz)
01:34PM
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
(Benzinga)
07:00AM
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
(GlobeNewswire)
10:13AM Loading…
Oct-01-24 10:13AM
Ascendis Pharma submits sBLA for growth hormone deficiency therapy
(Pharmaceutical Technology)
Sep-30-24 08:30AM
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) Presented at ASBMR 2024
(GlobeNewswire)
08:30AM
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency
(GlobeNewswire)
Sep-25-24 03:50PM
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
(Benzinga)
Sep-19-24 08:16PM
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
(GlobeNewswire)
Sep-18-24 04:04PM
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
(GlobeNewswire)
Sep-17-24 09:02AM
Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?
(Zacks) +5.03%
01:30AM
RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
(GuruFocus.com)
Sep-16-24 04:01PM
Ascendis Rockets And Hammers BioMarin On New Results For Growth Drug
(Investor's Business Daily) +17.07%
03:12PM
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
(Benzinga)
07:00AM
Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
(GlobeNewswire)
Sep-14-24 07:54PM
Ascendis Pharma A/S (ASND): Among Hedge Funds Top Biotech Stock Picks
(Insider Monkey)
Sep-13-24 08:30AM
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024
(GlobeNewswire)
Sep-11-24 05:37PM
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
(GlobeNewswire)
Sep-04-24 05:02PM
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
(Benzinga) -11.27%
04:48PM Loading…
04:48PM
Why Ascendis Pharma Stock Tumbled by 11% Today
(Motley Fool)
04:02PM
Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut
(Investor's Business Daily)
09:14AM
Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout
(Investor's Business Daily)
Sep-03-24 05:14PM
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
(GlobeNewswire)
05:06PM
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
(GlobeNewswire)
05:04PM
Ascendis Pharma Reports Second Quarter 2024 Financial Results
(GlobeNewswire)
Sep-02-24 09:01AM
Ascendis Pharma A/S (ASND) Q2 2024 Earnings Report Preview: What To Expect
(GuruFocus.com)
Aug-28-24 08:30AM
Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024
(GlobeNewswire)
Aug-14-24 12:31PM
Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath
(Zacks)
08:59AM
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
(Zacks)
Aug-13-24 04:32AM
FDA approves Ascendis Pharmas YORVIPATH for hypoparathyroidism
(Pharmaceutical Technology) +8.70%
Aug-12-24 04:55PM
Ascendis Pharma Zips Higher After FDA Approves Embattled Drug
(Investor's Business Daily)
07:30AM
FDA approves Ascendis drug for rare endocrine condition
(BioPharma Dive)
07:00AM
FDA Approves YORVIPATH (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults
(GlobeNewswire)
Jul-07-24 09:01AM
2 Biotech Stocks With Big FDA Decisions Approaching Heres What Analysts Expect
(TipRanks)
Jul-05-24 06:33AM
Pendopharm and Ascendis to distribute hypoparathyroidism treatment
(Pharmaceutical Technology)
Jul-04-24 12:48PM
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon PTH in Canada
(PR Newswire)
Jun-24-24 04:45PM
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
(GlobeNewswire)
Jun-21-24 01:02AM
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
(Insider Monkey) +5.12%
Jun-04-24 04:01PM
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
(GlobeNewswire)
Jun-03-24 04:01PM
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
(GlobeNewswire)
May-30-24 08:30AM
Ascendis to Spotlight Latest Updates for TransCon Rare Endocrinology Disease Portfolio at ENDO 2024
(GlobeNewswire)
May-15-24 01:57PM
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
(Benzinga)
10:44AM
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
(Zacks)
May-14-24 04:07PM
US Equity Markets Close Higher Tuesday as Producer Prices Rise
(MT Newswires) -5.45%
03:20PM
Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop
(MT Newswires)
02:47PM
UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy
(Reuters)
02:38PM
FDA extends review of Ascendis Pharma's hormone disorder therapy
(Reuters)
02:31PM
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism
(GlobeNewswire)
May-13-24 09:29AM
Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH
(MT Newswires)
08:30AM
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
(GlobeNewswire)
May-09-24 08:30AM
Latest Clinical and Quality-of-Life Data for TransCon PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
(GlobeNewswire)
May-06-24 09:59AM
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
(Insider Monkey)
May-03-24 03:49AM
Ascendis Pharma Q1 Net Loss Widens, Revenue Rises
(MT Newswires)
May-02-24 09:57PM
ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024
(InvestorPlace)
04:01PM
Ascendis Pharma Reports First Quarter 2024 Financial Results
(GlobeNewswire)
Apr-25-24 04:46PM
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
(GlobeNewswire)
Apr-24-24 11:33AM
Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism
(MT Newswires)
08:34AM
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
(Zacks)
08:30AM
United Kingdom's MHRA Approves YORVIPATH (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
(GlobeNewswire)
Apr-02-24 06:13AM
Biotech With 520% Sales Growth Nears Next Buy Point
(Investor's Business Daily)
Mar-22-24 12:09PM
Two Health Care Stocks Outperform S&P 500, Offer Entries
(Investor's Business Daily)
05:27AM
Ascendis Pharma A/S (ASND) Rose on Positive Trial Results
(Insider Monkey)
Mar-17-24 08:50AM
30 Biggest Biotechnology Companies in the World
(Insider Monkey)
Mar-07-24 08:14AM
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
(Insider Monkey)
Mar-04-24 08:30AM
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
(GlobeNewswire)
Feb-15-24 12:00PM
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?
(Zacks)
09:40AM
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
(Zacks)
Feb-08-24 10:07AM
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Feb-07-24 04:01PM
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
(GlobeNewswire)
08:30AM
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
(GlobeNewswire)
Feb-06-24 08:46AM
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
(Zacks)
Jan-31-24 04:15PM
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
(GlobeNewswire) +9.00%
04:01PM
Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
(GlobeNewswire)
Jan-29-24 08:30AM
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
(GlobeNewswire)
Jan-08-24 06:01PM
Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey
(GlobeNewswire) +6.57%
08:20AM
Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries
(GlobeNewswire)
Jan-07-24 05:45PM
Ascendis Pharma Introduces Vision 2030
(GlobeNewswire)
02:00PM
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries
(PR Newswire)
Dec-28-23 04:15PM
Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-20-23 08:30AM
Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon CNP (Navepegritide) at 100 g/kg/week
(GlobeNewswire)
Dec-19-23 08:30AM
TransCon hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency
(GlobeNewswire)
Dec-11-23 08:30AM
FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism
(GlobeNewswire)
Nov-29-23 04:30AM
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
(GlobeNewswire) +7.12%
Nov-20-23 08:00AM
Ascendis Pharma Announces European Commission Approval of YORVIPATH (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism
(GlobeNewswire)
Nov-15-23 08:00AM
Ascendis Pharma Resubmits NDA for TransCon PTH to the U.S. FDA
(GlobeNewswire)
Nov-08-23 02:07PM
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-07-23 04:01PM
Ascendis Pharma Reports Third Quarter 2023 Financial Results
(GlobeNewswire)
Nov-01-23 09:55AM
Does Ascendis Pharma A/S (ASND) Have the Potential to Rally 51.72% as Wall Street Analysts Expect?
(Zacks)
Oct-31-23 08:30AM
Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission
(GlobeNewswire)
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SINGEL STINAOfficerDec 10 '24Proposed Sale129.132,119273,621Dec 10 05:16 PM
JENSEN MICHAEL WOLFFOfficerDec 10 '24Proposed Sale129.132,119273,621Dec 10 05:07 PM
PEDERSEN ANNI LOTTE KIRSTINE SOfficerDec 10 '24Proposed Sale129.131,222157,794Dec 10 05:02 PM
SPROGOE KENNETTOfficerDec 10 '24Proposed Sale129.131,222157,794Dec 10 04:59 PM
SMITH SCOTT THOMASOfficerDec 10 '24Proposed Sale129.132,119273,621Dec 10 04:58 PM
JENSEN FLEMMING STEENOfficerDec 10 '24Proposed Sale129.131,222157,794Dec 10 04:55 PM
MIKKELSEN JAN MOLLEROfficerDec 10 '24Proposed Sale129.135,292683,342Dec 10 04:44 PM
JENSEN FLEMMING STEENOfficerDec 03 '24Proposed Sale131.379,3751,231,574Dec 03 04:35 PM
Hartvig Camilla HarderOfficerNov 19 '24Proposed Sale122.3819,4682,382,402Nov 19 04:08 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.